Schroeder Melanie, Hall Katie, Eliasson Lina, Bracey Sophia, Gunsoy Necdet B, Macey Jake, Jones Paul W, Ismaila Afisi S
Value Evidence and Outcomes, GlaxoSmithKline plc., Brentford, United Kingdom.
Patient Centred Outcomes, ICON plc., London, United Kingdom.
Chronic Obstr Pulm Dis. 2021 Jan;8(1):19-30. doi: 10.15326/jcopdf.8.1.2020.0131.
A wide range of therapeutic regimens, including single-inhaler triple therapies (SITTs), are now available for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Thus, an improved understanding of patient preferences may be valuable to inform physician prescribing decisions. This study was performed to assess the factors considered by patients when making decisions about their COPD treatments using qualitative techniques.
In the United Kingdom, United States and Germany, individual qualitative interviews (n=10 per country) and focus groups (1 per country; [United Kingdom, n=4; United States, n=6; Germany, n=6 participants]) were conducted. Interviews and focus groups were semi‑structured, lasting approximately 60 minutes, and focused on treatment preferences. Data were analyzed according to emerging themes identified from the interviews; qualitative thematic analysis of the data was performed using specialist software.
In interviews and focus groups, efficacy, ease of use, and lower frequency of use were favored attributes for current treatment, while side effects, medication taste, and more complex administration techniques were key dislikes. In interviews, most participants would consider a switch in medication, mainly for improved efficacy, but also to reduce medication frequency or following physician advice. Overall, efficacy and ease of use were the 2 most important attributes reported in interviews in all 3 countries.
Patients with COPD have preferences for certain attributes of medication, highlighting the multi-faceted nature of treatment effectiveness and the importance of the delivery device.These results were subsequently used to inform the design of a discrete choice experiment.
目前有多种治疗方案,包括单吸入器三联疗法(SITT),可用于慢性阻塞性肺疾病(COPD)的维持治疗。因此,更好地了解患者偏好可能有助于指导医生的处方决策。本研究旨在使用定性技术评估患者在做出COPD治疗决策时考虑的因素。
在英国、美国和德国开展了个人定性访谈(每个国家10例)和焦点小组访谈(每个国家1组;[英国,4名参与者;美国,6名参与者;德国,6名参与者])。访谈和焦点小组访谈采用半结构化形式,持续约60分钟,重点关注治疗偏好。根据访谈中确定的新出现的主题对数据进行分析;使用专业软件对数据进行定性主题分析。
在访谈和焦点小组访谈中,疗效、易用性和较低的使用频率是当前治疗中受青睐的属性,而副作用、药物味道和更复杂的给药技术是主要的厌恶因素。在访谈中,大多数参与者会考虑更换药物,主要是为了提高疗效,也为了减少用药频率或听从医生的建议。总体而言,疗效和易用性是所有3个国家访谈中报告的2个最重要的属性。
COPD患者对药物的某些属性有偏好,突出了治疗效果的多面性和给药装置的重要性。这些结果随后被用于指导离散选择实验的设计。